Singlet fission(SF)has potential applications in high-efficiency photo-energy harvesting applications,but its practical application is hindered by the limited number of materials.In this work,we explored the bay aroma...Singlet fission(SF)has potential applications in high-efficiency photo-energy harvesting applications,but its practical application is hindered by the limited number of materials.In this work,we explored the bay aromatic substitution strategy for the design of new perylenediimide(PDI)based SF materials.A series of PDI derivatives with biphenyl or naphthalene units substituted at the bay posi-tions were designed and synthesized to investigate the effects of aromatic substitutes on their photodynamic behaviours.The bay substitutions do not shift the energy level of the PDI core significantly but give rise to different intermolecular coupling strengths in the thin films and affect the intermolecular SF efficiency.Femtosecond transient absorption(fsTA)spectroscopy reveals that appro-priate spacing configuration from the bay aromatic substitution groups enhances the SF yields by promoting the interaction of neighbouring PDI cores.Triplet exciton yields of up to 183%have been obtained from these new PDI derivatives,making them po-tential candidates in future SF-based optoelectronics.展开更多
The tremendous success of mRNA vaccine during the COVID-19 pandemic has captured attention globally and highlighted the transformative potential of mRNA technology in addressing infectious diseases[1].In comparison to...The tremendous success of mRNA vaccine during the COVID-19 pandemic has captured attention globally and highlighted the transformative potential of mRNA technology in addressing infectious diseases[1].In comparison to conventional protein antibody-based therapies,the delivery of mRNA-encoding antibod-ies presents a cost-effective and versatile approach with several advantages.These include eliminating the laborious process of in vitro protein expression,enabling flexible manufacturing processes,and eliciting rapid therapeutic responses[2-4].However,the clinical application of mRNA-encoded antibodies for infectious diseases remains limited to date,only one such construct-mRNA-1944-has been assessed in non-human primates and approved for phase I clinical trial[5,6].Several challenges hampered the broader clinical application of mRNA-encoded antibody therapies,including the requirement for higher dosages for intravenous administration,limited pharmacodynamic and pharmacokinetics data,as well as the lack of safety and efficacy profiles in non-human primates[7].展开更多
基金supported by the National Natural Science Foundation of China(NSFC 51733004,51525303,21702085,21602093,21572086,22075117,92256202,U22A20399)the Fundamental Research Funds for the Central Universities(lzujbky-2022-kb01,Izujbky-2021-sp33,Izujbky-2021-27),and Supercomputing Center of Lanzhou University.
文摘Singlet fission(SF)has potential applications in high-efficiency photo-energy harvesting applications,but its practical application is hindered by the limited number of materials.In this work,we explored the bay aromatic substitution strategy for the design of new perylenediimide(PDI)based SF materials.A series of PDI derivatives with biphenyl or naphthalene units substituted at the bay posi-tions were designed and synthesized to investigate the effects of aromatic substitutes on their photodynamic behaviours.The bay substitutions do not shift the energy level of the PDI core significantly but give rise to different intermolecular coupling strengths in the thin films and affect the intermolecular SF efficiency.Femtosecond transient absorption(fsTA)spectroscopy reveals that appro-priate spacing configuration from the bay aromatic substitution groups enhances the SF yields by promoting the interaction of neighbouring PDI cores.Triplet exciton yields of up to 183%have been obtained from these new PDI derivatives,making them po-tential candidates in future SF-based optoelectronics.
基金supported by the National Key Research and Development Project of China(2022YFC2304100 and 2021YFC2302400)the National Natural Science Foundation of China(82371833,82350801,and 82222041)+1 种基金Cheng-Feng Qin was supported by the National Science Fund for Distinguished Young Scholars(81925025)the Innovation Fund for Medical Sciences(2019-I2M-5-049)from the Chinese Academy of Medical Sciences.
文摘The tremendous success of mRNA vaccine during the COVID-19 pandemic has captured attention globally and highlighted the transformative potential of mRNA technology in addressing infectious diseases[1].In comparison to conventional protein antibody-based therapies,the delivery of mRNA-encoding antibod-ies presents a cost-effective and versatile approach with several advantages.These include eliminating the laborious process of in vitro protein expression,enabling flexible manufacturing processes,and eliciting rapid therapeutic responses[2-4].However,the clinical application of mRNA-encoded antibodies for infectious diseases remains limited to date,only one such construct-mRNA-1944-has been assessed in non-human primates and approved for phase I clinical trial[5,6].Several challenges hampered the broader clinical application of mRNA-encoded antibody therapies,including the requirement for higher dosages for intravenous administration,limited pharmacodynamic and pharmacokinetics data,as well as the lack of safety and efficacy profiles in non-human primates[7].
